US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Tvardi Therapeutics Inc

1.85

-0.0300-1.60%

Pre-market: 1.81-0.0400-2.16%04:57 EDT

Volume:98.76K

Turnover:184.99K

Market Cap:24.68M

PE:-0.67

High:1.91

Open:1.89

Low:1.84

Close:1.88

52wk High:43.65

52wk Low:1.50

Shares:13.34M

Float Shares:5.67M

Volume Ratio:0.67

T/O Rate:1.74%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.7737

EPS(LYR):-3.2600

ROE:-126.19%

ROA:-55.51%

PB:2.94

PE(LYR):-0.57

Loading ...

Overview Company News Filings

Tvardi Therapeutics Inc - Tti-109 Topline Data and Clinical Strategy Announcement Expected in June 2026

THOMSON REUTERS

Tvardi Therapeutics Inc - Topline Data From Phase 2 Trial of Tti-101 in Hepatocellular Carcinoma (Hcc) on Track for 2H 2026

THOMSON REUTERS

Tvardi Therapeutics Inc: Cash Runway Expected to Be Sufficient to Fund Operations Through Clinical Readouts and Into Q4 2026

THOMSON REUTERS

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

THOMSON REUTERS

Tvardi Therapeutics Files $200 Million Mixed Shelf

MT Newswires Live

Tvardi Therapeutics files $200M mixed securities shelf

Tvardi Therapeutics Inc - May Offer up to $200 Mln in Securities - SEC Filing

THOMSON REUTERS

Tvardi Therapeutics : Barclays Cuts Target Price to $3 From $4

THOMSON REUTERS

Tvardi Therapeutics to attend Raymond James Biotech Innovation Symposium investor meetings

Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development

Tvardi Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX)

Barclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD)

Tvardi Therapeutics reports larger-than-expected Q4 net loss

Tvardi FY25 net loss narrows 38% to $18 million

Tvardi Therapeutics Inc - Topline Data From Tti-101 Phase 2 Hcc Trial Anticipated in H2 2026

THOMSON REUTERS

Press Release: Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Tvardi Therapeutics Inc expected to post a loss of 65 cents a share - Earnings Preview

Tvardi Therapeutics Inc expected to post a loss of 65 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/TVRD/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":1.85,"timestamp":1788465600000,"preClose":1.88,"halted":0,"volume":98759,"hourTrading":{"tag":"盘前","latestPrice":1.81,"preClose":1.85,"latestTime":"04:57 EDT","volume":6,"amount":10.6099998,"timestamp":1788512232005,"change":-0.04,"changeRate":-0.021622,"amplitude":0.027027},"delay":0,"changeRate":-0.015957446808510536,"floatShares":5671300,"shares":13338900,"eps":-2.773725,"marketStatus":"Pre-Mkt","change":-0.03,"latestTime":"09-04 05:42:07 EDT","open":1.89,"high":1.91,"low":1.84,"amount":184986.2334684,"amplitude":0.037234,"askPrice":2.05,"askSize":100,"bidPrice":1.65,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.773725,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788528600000},"marketStatusCode":1,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":1.85,"preHourTrading":{"tag":"盘前","latestPrice":1.81,"preClose":1.85,"latestTime":"04:57 EDT","volume":6,"amount":10.6099998,"timestamp":1788512232005,"change":-0.04,"changeRate":-0.021622,"amplitude":0.027027},"postHourTrading":{"tag":"盘后","latestPrice":1.887,"preClose":1.85,"latestTime":"19:30 EDT","volume":2768,"amount":5177.7338,"timestamp":1788478206525,"change":0.037,"changeRate":0.02,"amplitude":0.02},"volumeRatio":0.6736418907685859,"impliedVol":1.9457,"impliedVolPercentile":0.629},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":5671300,"roa":"-55.51%","roe":"-126.19%","lyrEps":-3.259999,"volumeRatio":0.6736418907685859,"shares":13338900,"dividePrice":0,"high":1.91,"amplitude":0.037234,"preClose":1.88,"low":1.84,"week52Low":1.5,"pbRate":"2.94","week52High":43.65,"institutionHeld":0,"latestPrice":1.85,"eps":-2.773725,"divideRate":0,"volume":98759,"delay":0,"ttmEps":-2.773725,"open":1.89,"prevYearClose":4.3,"prevWeekClose":1.82,"prevMonthClose":1.8,"prevQuarterClose":1.9,"fiveDayClose":1.8,"twentyDayClose":1.85,"sixtyDayClose":2.78},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"TVRD","fiscalQuarterEnding":"2026/06","expectedEps":-0.65,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2026-05-08","symbol":"TVRD","fiscalQuarterEnding":"2026/03","expectedEps":-0.65,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":-0.73},{"market":"US","date":"2026-03-31","symbol":"TVRD","fiscalQuarterEnding":"2025/12","expectedEps":-0.55,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"post","actualEps":-0.78},{"market":"US","date":"2025-11-13","symbol":"TVRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2025-08-14","symbol":"TVRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":1}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.125,"sell":0.125,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":8,"updateTime":1783569600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVRD","date":"2026-09-03","current":-0.666973,"percent":0.949458,"low":-17.054928,"twenty":-2.933989,"median":-1.660569,"eighty":-1.480963,"high":-0.658706,"avg":-3.60201,"sd":4.268133,"marketCap":25077212},"quantilePoints":[{"date":"2025-08-01","current":-6.984237,"twenty":-7.018674,"median":-6.984237,"eighty":-6.867475,"marketCap":242869870},{"date":"2025-08-08","current":-6.220168,"twenty":-7.05634,"median":-6.986928,"eighty":-6.651705,"marketCap":216300131},{"date":"2025-08-15","current":-6.400424,"twenty":-7.003609,"median":-6.690985,"eighty":-6.397734,"marketCap":222568344},{"date":"2025-08-22","current":-10.573024,"twenty":-9.576632,"median":-6.986928,"eighty":-6.42948,"marketCap":249861702},{"date":"2025-08-29","current":-12.013447,"twenty":-10.759129,"median":-7.048807,"eighty":-6.480866,"marketCap":283901784},{"date":"2025-09-05","current":-12.078921,"twenty":-11.588463,"median":-7.134899,"eighty":-6.493511,"marketCap":285449060},{"date":"2025-09-12","current":-14.047103,"twenty":-11.928926,"median":-9.803211,"eighty":-6.612426,"marketCap":331961128},{"date":"2025-09-19","current":-15.372451,"twenty":-12.457478,"median":-10.666275,"eighty":-6.823352,"marketCap":363281754},{"date":"2025-09-26","current":-14.606606,"twenty":-13.432046,"median":-11.499578,"eighty":-6.955181,"marketCap":345183308},{"date":"2025-10-03","current":-14.82882,"twenty":-14.620891,"median":-11.737664,"eighty":-6.987466,"marketCap":350434671},{"date":"2025-10-10","current":-17.054928,"twenty":-14.850248,"median":-11.943013,"eighty":-6.991233,"marketCap":403042070},{"date":"2025-10-17","current":-2.571334,"twenty":-14.850248,"median":-11.769409,"eighty":-6.823352,"marketCap":60765765},{"date":"2025-10-24","current":-2.047544,"twenty":-14.833582,"median":-11.58886,"eighty":-6.422216,"marketCap":48387554},{"date":"2025-10-31","current":-1.849138,"twenty":-14.74787,"median":-11.130543,"eighty":-4.843171,"marketCap":43698837},{"date":"2025-11-07","current":-1.563435,"twenty":-14.662953,"median":-10.195062,"eighty":-2.595143,"marketCap":36947086},{"date":"2025-11-14","current":-1.631573,"twenty":-14.620891,"median":-9.523459,"eighty":-2.06421,"marketCap":38557323},{"date":"2025-11-21","current":-1.515552,"twenty":-14.489944,"median":-7.06764,"eighty":-1.887232,"marketCap":35836734},{"date":"2025-11-28","current":-1.634574,"twenty":-14.266143,"median":-6.990963,"eighty":-1.811838,"marketCap":38651137},{"date":"2025-12-05","current":-1.658378,"twenty":-13.805842,"median":-6.911597,"eighty":-1.667399,"marketCap":39214017},{"date":"2025-12-12","current":-1.781368,"twenty":-13.436014,"median":-6.493242,"eighty":-1.662637,"marketCap":42122234},{"date":"2025-12-19","current":-1.543324,"twenty":-13.412999,"median":-6.400424,"eighty":-1.660082,"marketCap":36493428},{"date":"2025-12-26","current":-1.5949,"twenty":-13.32332,"median":-6.349307,"eighty":-1.639335,"marketCap":37713002},{"date":"2026-01-02","current":-1.705987,"twenty":-13.031267,"median":-2.777676,"eighty":-1.642509,"marketCap":40339779},{"date":"2026-01-09","current":-1.678216,"twenty":-12.62652,"median":-2.62292,"eighty":-1.634574,"marketCap":39683085},{"date":"2026-01-16","current":-1.789303,"twenty":-12.344784,"median":-2.448323,"eighty":-1.634574,"marketCap":42309861},{"date":"2026-01-23","current":-1.91626,"twenty":-12.181298,"median":-2.07532,"eighty":-1.634574,"marketCap":45311891},{"date":"2026-01-30","current":-1.547291,"twenty":-12.091222,"median":-1.95231,"eighty":-1.634574,"marketCap":36587241},{"date":"2026-02-06","current":-1.408431,"twenty":-12.026542,"median":-1.896756,"eighty":-1.617117,"marketCap":33303771},{"date":"2026-02-13","current":-1.475877,"twenty":-11.900753,"median":-1.8627,"eighty":-1.598129,"marketCap":34898599},{"date":"2026-02-20","current":-1.424301,"twenty":-11.810677,"median":-1.847154,"eighty":-1.590139,"marketCap":33679024},{"date":"2026-02-27","current":-1.606802,"twenty":-11.750362,"median":-1.836912,"eighty":-1.577443,"marketCap":37994443},{"date":"2026-03-06","current":-1.5949,"twenty":-11.649572,"median":-1.807157,"eighty":-1.573476,"marketCap":37713002},{"date":"2026-03-13","current":-1.458024,"twenty":-11.588463,"median":-1.789617,"eighty":-1.565651,"marketCap":34476439},{"date":"2026-03-20","current":-1.460008,"twenty":-11.482118,"median":-1.781368,"eighty":-1.559193,"marketCap":34523345},{"date":"2026-03-27","current":-1.321148,"twenty":-11.243237,"median":-1.741999,"eighty":-1.553639,"marketCap":31239875},{"date":"2026-04-02","current":-1.545187,"twenty":-10.944836,"median":-1.71789,"eighty":-1.546029,"marketCap":28144032},{"date":"2026-04-10","current":-1.524584,"twenty":-10.628975,"median":-1.704004,"eighty":-1.543324,"marketCap":27768778},{"date":"2026-04-17","current":-1.6585,"twenty":-10.270654,"median":-1.682478,"eighty":-1.543324,"marketCap":30207927},{"date":"2026-04-24","current":-1.550337,"twenty":-9.805989,"median":-1.678216,"eighty":-1.544069,"marketCap":28237845},{"date":"2026-05-01","current":-1.622446,"twenty":-9.682977,"median":-1.674248,"eighty":-1.546029,"marketCap":29551233},{"date":"2026-05-08","current":-2.168412,"twenty":-8.568035,"median":-1.676379,"eighty":-1.548509,"marketCap":39495458},{"date":"2026-05-15","current":-2.406252,"twenty":-7.115528,"median":-1.682478,"eighty":-1.550705,"marketCap":37150122},{"date":"2026-05-22","current":-2.181425,"twenty":-7.071406,"median":-1.707971,"eighty":-1.552845,"marketCap":33679024},{"date":"2026-05-29","current":-2.120661,"twenty":-7.037507,"median":-1.719873,"eighty":-1.555226,"marketCap":32740890},{"date":"2026-06-05","current":-1.871529,"twenty":-6.991771,"median":-1.746061,"eighty":-1.555226,"marketCap":28894539},{"date":"2026-06-12","current":-1.646703,"twenty":-6.988542,"median":-1.736886,"eighty":-1.555278,"marketCap":25423442},{"date":"2026-06-18","current":-1.56771,"twenty":-6.984237,"median":-1.719873,"eighty":-1.555488,"marketCap":24203867},{"date":"2026-06-26","current":-1.434029,"twenty":-6.911597,"median":-1.705987,"eighty":-1.555226,"marketCap":22139971},{"date":"2026-07-02","current":-1.184897,"twenty":-6.735107,"median":-1.689237,"eighty":-1.549728,"marketCap":18293620},{"date":"2026-07-10","current":-2.30903,"twenty":-6.533867,"median":-1.695629,"eighty":-1.54687,"marketCap":35649107},{"date":"2026-07-17","current":-1.871529,"twenty":-6.492435,"median":-1.709955,"eighty":-1.549728,"marketCap":28894539},{"date":"2026-07-24","current":-1.555557,"twenty":-6.447775,"median":-1.713922,"eighty":-1.551074,"marketCap":24016240},{"date":"2026-07-31","current":-1.276043,"twenty":-6.414952,"median":-1.704004,"eighty":-1.544474,"marketCap":19700822},{"date":"2026-08-07","current":-1.124133,"twenty":-6.392353,"median":-1.682478,"eighty":-1.541737,"marketCap":17355486},{"date":"2026-08-14","current":-1.075522,"twenty":-6.364373,"median":-1.67765,"eighty":-1.526306,"marketCap":16604978},{"date":"2026-08-21","current":-0.658706,"twenty":-6.271824,"median":-1.674248,"eighty":-1.509204,"marketCap":17167859},{"date":"2026-08-28","current":-0.921233,"twenty":-4.310985,"median":-1.663144,"eighty":-1.491321,"marketCap":24010097},{"date":"2026-09-03","current":-0.962177,"twenty":-2.933989,"median":-1.660569,"eighty":-1.480963,"marketCap":25077212}],"updateTime":1788514927217},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVRD\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633588464","title":"Tvardi Therapeutics Inc - Tti-109 Topline Data and Clinical Strategy Announcement Expected in June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633588464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633588464?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:00","pubTimestamp":1778238002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA9MM6BK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633458817","title":"Tvardi Therapeutics Inc - Topline Data From Phase 2 Trial of Tti-101 in Hepatocellular Carcinoma (Hcc) on Track for 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633458817","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633458817?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:00","pubTimestamp":1778238002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA9MM6BK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633458810","title":"Tvardi Therapeutics Inc: Cash Runway Expected to Be Sufficient to Fund Operations Through Clinical Readouts and Into Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633458810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633458810?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:00","pubTimestamp":1778238002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA9MM6BK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633301430","title":"Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633301430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633301430?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:00","pubTimestamp":1778238002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA9MM6BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632864791","title":"Tvardi Therapeutics Files $200 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2632864791","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632864791?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:19","pubTimestamp":1777666796,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics (TVRD) filed a registration statement late Friday for the sale of $200 million of securities from time to time.The securities cover common and preferred stocks, debt securities, and warrants.Net proceeds will be used for general corporate purposes, according to the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","TVRD","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647960","title":"Tvardi Therapeutics files $200M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647960","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647960?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:11","pubTimestamp":1777666284,"startTime":"0","endTime":"0","summary":"16:07 EDT Tvardi Therapeutics (TVRD) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tvardi-therapeutics-files-200m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tvardi-therapeutics-files-200m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4539","TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632642037","title":"Tvardi Therapeutics Inc - May Offer up to $200 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2632642037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632642037?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:06","pubTimestamp":1777665997,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nFWN41D1UB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628414627","title":"Tvardi Therapeutics : Barclays Cuts Target Price to $3 From $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2628414627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628414627?lang=en_us&edition=fundamental","pubTime":"2026-04-20 18:24","pubTimestamp":1776680680,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nAZN4SRN4H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506964","title":"Tvardi Therapeutics to attend Raymond James Biotech Innovation Symposium investor meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506964","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506964?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:03","pubTimestamp":1775131412,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics management will hold one-on-one investor meetings at Raymond James Biotech Innovation Symposium in New York City on April 14, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL9q0l5G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","LU2210149790.SGD","LU2095319765.USD","BK4007","LU2265009873.SGD","LU1804176565.USD","IE00B3QW5Z07.USD","LU0314104364.USD","LU0971096721.USD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","LU1363072403.SGD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4585","BK4127","IE00BKPKM429.USD","SG9999014013.SGD","BK4588","IE00BN0W2T93.GBP","BK4112","RJF","SG9999014021.USD","TVRD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624788715","title":"Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2624788715","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624788715?lang=en_us&edition=fundamental","pubTime":"2026-04-02 14:00","pubTimestamp":1775109613,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc. (TVRD) has disclosed a new risk, in the Regulation category. Tvardi Therapeutics Inc. faces the risk that stricter enforce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tvardi-therapeutics-warns-animal-welfare-rules-could-raise-costs-and-delay-drug-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tvardi-therapeutics-warns-animal-welfare-rules-could-raise-costs-and-delay-drug-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TVRD","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624535544","title":"Tvardi Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2624535544","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624535544?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:01","pubTimestamp":1775077279,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryTvardi Therapeutics Inc TVRD.OQ reported a quarterly adjusted loss of 78 cents per share for the quarter end","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nL8N40K2N3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624059016","title":"Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624059016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624059016?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:20","pubTimestamp":1775042404,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tvardi Therapeutics (TVRD) and Forte Biosciences (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tvardi-therapeutics-tvrd-and-forte-biosciences-fbrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tvardi-therapeutics-tvrd-and-forte-biosciences-fbrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LABU","BK4139","LU0029874061.USD","FBRX","LU0128526141.USD","BK4588","BK4137","BK4581","BK4585","BK4007","TVRD","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624591306","title":"Barclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624591306","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624591306?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:27","pubTimestamp":1775035636,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout maintained a Hold rating on Tvardi Therapeutics today and set a price target of $4.00. Darout covers the Healthcare s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-hold-rating-on-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-hold-rating-on-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537405","title":"Tvardi Therapeutics reports larger-than-expected Q4 net loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537405","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537405?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:12","pubTimestamp":1774987979,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics reports larger-than-expected Q4 net lossOverviewUS biopharma's Q4 net loss narrowed but missed analyst expectationsR&D expenses fell on lower TTI-101 clinical costs; G&A expenses r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL1N40J16T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537107","title":"Tvardi FY25 net loss narrows 38% to $18 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537107","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537107?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:10","pubTimestamp":1774987831,"startTime":"0","endTime":"0","summary":"Tvardi reported full-year 2025 net loss of $18 million, narrowing from $29 million a year earlier.Fourth-quarter net loss shrank to $7.3 million from $13 million, with research and development expense falling to $5.5 million from $8.6 million.General and administrative expense in 2025 climbed to $8.7 million from $4.5 million due to higher professional fees tied to merger-related legal, accounting, and audit costs.Cash, cash equivalents, and short-term investments totaled $31 million at year-end, with runway expected to fund operations into Q4 2026.TTI-109 healthy-volunteer topline data are expected in Q2 2026, with REVERT LIVER CANCER Phase 1b/2 topline results for TTI-101 now targeted for H2 2026 to allow additional data maturation.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL9grJ8f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","NDAQ","SG9999014013.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4585","TVRD","LU2210149790.SGD","BK4007","BK4588","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BN0W2V16.EUR","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624305355","title":"Tvardi Therapeutics Inc - Topline Data From Tti-101 Phase 2 Hcc Trial Anticipated in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624305355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624305355?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:01","pubTimestamp":1774987261,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA1LQWFJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624324537","title":"Press Release: Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624324537","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624324537?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:01","pubTimestamp":1774987260,"startTime":"0","endTime":"0","summary":"Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026. Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma  are anticipated in H2 2026. Cash runway expected to be sufficient to fund operations into Q4 2026 after clinical readouts. TTI-101 was associated with a 9.4% baseline-weighted reduction in. TTI-109, is ongoing, with topline data anticipated in the second quarter. \"Further analysis of data from our Phase 2 IPF trial of TTI-101 that we announced in October revealed compelling trends. These data give us optimism for TTI-109, which has been developed to enhance TTI-101's ability to target STAT3 as a more efficient delivery vehicle with the potential to improve tolerability.\". \"At the same time, we eagerly await data from our ongoing Phase 2 REVERT LIVER CANCER trial, with a data readout expected in the second half of this year to allow for further data maturation. Interim results from this study have already shown cl","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD","HCC","BK4539","BK4139","LENZ","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623260403","title":"Tvardi Therapeutics Inc  expected to post a loss of 65 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2623260403","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623260403?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:07","pubTimestamp":1774901228,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc  expected to post a loss of65cents a share - Earnings Preview Tvardi Therapeutics Inc TVRD.OQ TVRD.O is expected to  show a fall in quarterly revenue when it reports  results o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL8N40I1X0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617630918","title":"Tvardi Therapeutics Inc  expected to post a loss of 65 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2617630918","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617630918?lang=en_us&edition=fundamental","pubTime":"2026-03-07 04:39","pubTimestamp":1772829550,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc  expected to post a loss of65cents a share - Earnings Preview Tvardi Therapeutics Inc TVRD.OQ TVRD.O is expected to  show a fall in quarterly revenue when it reports  results o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL8N3ZU2IF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":59,"code":"91000000","status":"200"}]}}